Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 9/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.45 |
| ▸ | FLT1 | P17948 | 4/20 | 0.45 |
| ▸ | FGFR2 | P21802 | 4/20 | 0.45 |
| ▸ | FGFR4 | P22455 | 4/20 | 0.45 |
| ▸ | FGFR3 | P22607 | 4/20 | 0.45 |
| ▸ | FLT4 | P35916 | 4/20 | 0.45 |
| ▸ | KDR | P35968 | 4/20 | 0.45 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.34 |
| ▸ | FYN | P06241 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4664598 | 0.95 | SRC (0.54) | SRCFGFR1FLT1FGFR2FGFR4 | |
| SCHEMBL1893907 | 0.78 | SRC (0.51) | SRCFGFR1FLT1FGFR4KDR | |
| Hydrochloric Acid SCHEMBL6433816 | 0.77 | SRC (0.50) | SRCFGFR1FLT1FGFR4KDR | |
| SCHEMBL4664563 | 0.77 | EHMT2 (0.52) | SRCPDGFRBEGFRMAP2K1FYN | |
| SCHEMBL4665965 | 0.76 | FLT1 (0.42) | SRCFGFR1FLT1FGFR2FGFR4 | |
| SCHEMBL4664106 | 0.75 | WEE2 (0.54) | SRCFLT1KDRPDGFRBEGFR | |
| SCHEMBL6464138 | 0.74 | SRC (0.57) | SRCEGFRMAP2K1FYN | |
| SCHEMBL4666487 | 0.74 | KDR (0.53) | SRCFGFR1FLT1FGFR2FGFR4 | |
| SCHEMBL4666041 | 0.74 | FLT1 (0.42) | SRCFGFR1FLT1FGFR2FGFR4 | |
| SCHEMBL1891499 | 0.74 | PDGFRA (0.58) | FLT4KDRPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312273-A1 | Quinoline Derivatives Having Vegf Inhibiting Activity | HENNEQUIN LAURENT FRANCOIS ANDRE | 2008-12-18 | — | — | US | disclosed |
| US-20080312273-A1 | Quinoline Derivatives Having Vegf Inhibiting Activity | HENNEQUIN LAURENT FRANCOIS ANDRE | 2008-12-18 | — | — | US | disclosed |
| US-20080312273-A1 | Quinoline Derivatives Having Vegf Inhibiting Activity | HENNEQUIN LAURENT FRANCOIS ANDRE | 2008-12-18 | — | — | US | disclosed |
| US-7371765-B2 | Quinoline derivatives having VEGF inhibiting activity | ASTRAZENECA AB (SE) | 2008-05-13 | — | — | US | disclosed |
| US-7371765-B2 | Quinoline derivatives having VEGF inhibiting activity | ASTRAZENECA AB (SE) | 2008-05-13 | — | — | US | disclosed |
| US-7371765-B2 | Quinoline derivatives having VEGF inhibiting activity | ASTRAZENECA AB (SE) | 2008-05-13 | — | — | US | disclosed |
| US-20030199491-A1 | Quinoline derivatives having vegf inhibiting activity | ASTRAZENECA AB (SE) | 2003-10-23 | — | — | US | disclosed |
| EP-1313726-A1 | QUINOLINE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY | AstraZeneca AB (SE) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002012226-A1 | QUINOLINE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY | ASTRAZENECA AB (SE) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312273-A1 | Quinoline Derivatives Having Vegf Inhibiting Activity | VEGFA, FLT1, FLT4 | SRC 1933/4885FGFR1 99/4885FLT1 2/4885 |
| US-20030199491-A1 | Quinoline derivatives having vegf inhibiting activity | VEGFA, FLT1, FLT4 | SRC 3356/4885FGFR1 203/4885FLT1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.